探索蛋白质对多巴胺聚合物的复杂影响:调节的机制和策略
Chenxu Zhu1, Huaisyuan Xie1, Yihan Zhang1
1Beijing National Laboratory for Molecular Sciences and MOE Key Laboratory of Bioorganic Chemistry and Molecular Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
The journal of physical chemistry. B
|March 15, 2024
概括
蛋白质显著影响聚多巴胺 (pDA) 的形成. 特定的蛋白质特征,如阿维丁的生物结位和红蛋白质的结构,抑制pDA,为生物材料设计提供了洞察力.
科学领域:
- 材料科学 材料科学 材料科学
- 生物化学 生化学
- 聚合物化学 聚合物化学
背景情况:
- 聚多巴胺 (pDA) 是一种具有广泛应用的多功能生物材料.
- 多巴胺聚合是复杂的,受外部因素,特别是蛋白质的影响.
- 了解蛋白相互作用对于控制pDA合成至关重要.
研究的目的:
- 为了研究特定蛋白质表面特征如何影响多巴胺聚合.
- 为了确定控制蛋白质诱导的pDA形成抑制的关键相互作用.
- 探索使用蛋白质特征调节pDA合成的策略.
主要方法:
- 研究了各种蛋白质 (阿维丁,中性激素,核酶,红蛋白) 对多巴胺聚合物的抑制作用.
- 研究了生物素结合部位和蛋白质脱糖化作用.
- 使用DNA和生物素作为缓解剂.
- 假设的相互作用机制包括结,静电,-π和疏水相互作用.
主要成果:
- 阿维丁和中性丁显示出显著的抑制作用,主要是由于它们的生物素结合部位;生物素结合逆转了这种效应.
- 核酶抑制了pDA的形成,但DNA的引入减轻了这一障碍.
- 红素 (EPO) 诱导了显著的阻断效应,即使在脱糖化后也持续存在.
- 确定了蛋白质和多巴胺寡合体之间的潜在结合相互作用.
结论:
- 特定的蛋白质结构元素,如结合点和糖化,极大地影响多巴胺聚合.
- 蛋白质-pDA相互作用是由非共价力的组合介导的.
- 这些发现为定制生物材料开发提供了对pDA形成的机制理解和战略控制.
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
02:04Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
02:54Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K